TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02277223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.
Study: NCT02274012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Study: NCT01605240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and Ibuprofen
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and Codeine
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
Study: NCT03298958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Subject will be randomized to one of the 2 arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subject will be randomized to one of the 2 arms
Study: NCT02541357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery
Study: NCT01288937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
Study: NCT02854332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS session
Description: Direct current transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS session
Description: Repetitive transcranial magnetic stimulation.
Study: NCT02909335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.
Study: NCT00647985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Tablets 180 mg
Description: 180mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra® Tablets 180 mg
Description: 180mg, single dose fed
Study: NCT03389321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas)
Description: Riociguat film-coated tablets for oral administration at a strength of 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan (Opsumit)
Description: Macitentan film-coated tablets for oral administration at a strength of 10 mg
Study: NCT02909335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone, Prednisone or Methylprednisolone
Description: Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone, Prednisone or Methylprednisolone
Description: Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
Study: NCT01579786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetaminophen and acupuncture
Description: All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
Study: NCT04299646

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Steretactic radiotherapy
Description: Steretactic radiotherapy
Study: NCT03342638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of participant's own stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of participant's own stem cells
Study: NCT04075123

Intervention type: OTHER
Intervention: CPAP
Description: The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
Study: NCT04424381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet [Xarelto]
Description: The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
Study: NCT01924650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose
Study: NCT00620841

Intervention type: OTHER
Intervention: genotyping
Description: Restriction fragment lenght polymorphisms
Study: NCT03512665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Full dose supplement
Description: A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Supplement
Description: A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Oil
Description: A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
Study: NCT04050826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)
Description: Topical application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 1 sample will be taken pre-dose and 12 samples post-dose.
Study: NCT00003857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03044379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine gel (0.05%)
Description: MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Universal HEC placebo gel
Study: NCT01298128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: NuvaRIng 21 days for IVF pre-treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marvelon
Description: marvelon 21 daily
Study: NCT01090453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: 3 doses given at 2, 4 and 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: 3 co-administered doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13®
Description: 3 co-administered doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: 3 doses given at 2, 4 and 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: 3 co-administered doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, two doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, two doses
Study: NCT01733654

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
Study: NCT00522275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
Study: NCT00389558

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection efficacy using Biseptine
Description: Detersion and antiseptic application when changing catheter dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection efficacy using Amukin
Description: Detersion and antiseptic application when changing catheter dressing
Study: NCT04594161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Nephrostomy
Description: A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J catheter
Description: A Double J catheter will be placed in patients with obstructive urolithiasis
Study: NCT01507168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv Days 1 and 8, and every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33
Description: 1600 mg iv Day 1 and 8, and every 2 weeks thereafter
Study: NCT00466518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of sitagliptin
Description: Sitagliptin 100 mg daily for 3 months
Study: NCT01192438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-based thermotherapy
Description: MRI-guided transperineal placement of a laser probe into the prostate
Study: NCT05110092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: leg resistance combined with breathing exercise training
Description: The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
Study: NCT00754845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01049126

Intervention type: OTHER
Intervention: ChemoFx
Description: Chemoresponse Marker Assay
Study: NCT02568241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
Study: NCT03030300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin 30R;Pioglitazone;Metformin
Description: * Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone.
Study: NCT01181050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
Study: NCT03510208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Fluorescence Imaging
Description: Undergo NIR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Fluorescence Imaging
Description: Undergo NIR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Fluorescence Imaging
Description: Undergo NIR imaging

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POINPOINT-IR9000
Description: Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POINPOINT-IR9000
Description: Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POINPOINT-IR9000
Description: Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table).
Study: NCT03964454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)
Description: Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WIC support + home-based individual support (SC)
Description: Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
Study: NCT02457221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsules
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide injections
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral
Study: NCT04299646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pursuit of ongoing systemic treatment
Description: Pursuit of ongoing systemic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pursuit of ongoing systemic treatment
Description: Pursuit of ongoing systemic treatment
Study: NCT03291431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst transcranial magnetic stimulation
Description: 20 iTBS sessions (active or sham) administered over the course of 2 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent theta burst transcranial magnetic stimulation
Description: 20 iTBS sessions (active or sham) administered over the course of 2 weeks